Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52‐Week Results From a Randomized, Placebo‐Controlled, Phase 2b Dose‐Ranging Study
In patients with SjD, ianalumab 300 mg demonstrated sustained efficacy through week 52 and a favorable safety profile up to two years of follow-up.
Authors
- Benjamin A. Fisher (ORCID: https://orcid.org/0000-0003-4631-549X)
- Wolfgang Hueber
- Salvatore De Vita (ORCID: https://orcid.org/0009-0004-3623-4674)
- Thomas Grader‐Beck (ORCID: https://orcid.org/0000-0002-4056-6207)
- Robert I. Fox (ORCID: https://orcid.org/0000-0001-6222-7954)
- Filipe Barcelos (ORCID: https://orcid.org/0000-0002-3764-0808)
- Monika Sopala (ORCID: https://orcid.org/0000-0001-9587-7953)
- Simon Bowman (ORCID: https://orcid.org/0000-0001-9880-9948)
- G. Junge (ORCID: https://orcid.org/0000-0002-8938-3612)
- Xavier Mariette (ORCID: https://orcid.org/0000-0002-4244-5417)
- Wen‐Lin Luo
- Alexandre Avraméas (ORCID: https://orcid.org/0000-0003-4094-5829)
- J. Woznicki
- Robert J. Moots (ORCID: https://orcid.org/0000-0001-7019-6211)
- Hendrik Schulze‐Koops (ORCID: https://orcid.org/0000-0002-1681-491X)
- Thomas Dörner (ORCID: https://orcid.org/0000-0002-6478-7725)
- Athena Papas (ORCID: https://orcid.org/0000-0002-5638-4387)
Institutions
- Tufts University (US)
- Novartis (Switzerland) (CH)
- University of Udine (IT)
- University Hospitals Birmingham NHS Foundation Trust (GB)
- Johns Hopkins University (US)
- University of Liverpool (GB)
- Edge Hill University (GB)
- Université Paris-Saclay (FR)
- Aintree University Hospital (GB)
- Scripps Memorial Hospital (US)
- Novartis (United States) (US)
- Instituto Português de Malacologia (PT)
- Bicêtre Hospital (FR)
- NIHR Birmingham Biomedical Research Centre (GB)
- Instituto Português de Reumatologia
- Charité - Universitätsmedizin Berlin (DE)
- University of Birmingham (GB)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2024-11-18
- DOI
- https://doi.org/10.1002/art.43059
- Citations
- 9
- Primary Topic
- Salivary Gland Disorders and Functions
- Type
- article
- Field-Weighted Citation Impact
- 2.94